Skip to main content

Table 2 Use of pegfilgrastim prophylaxis in cycle 1, cycle 2, cycles 3+, last cycle, and all cycles, respectively, overall and by FN occurrence in a prior cycle*

From: Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study

  Commercial Medicare
  Pegfilgrastim Use   Pegfilgrastim Use
No. (%) in Each Category No Yes Unadjusted OR (95% CI) No. (%) in Each Category No Yes Unadjusted OR (95% CI)
Cycle 1
 FN Events Prior to Cycle 1
  No 50,778 (100%) 16,512 (33%) 34,266 (67%) 71,037 (100%) 20,195 (28%) 50,842 (72%)
  Yes
Cycle 2 41,769 11,719 (28%) 30,050 (72%)   59,412 15,193 (26%) 44,219 (74%)  
 FN Events Prior to Cycle 2
  No 40,123 (96%) 11,482 (29%) 28,641 (71%) 55,488 (93%) 14,483 (26%) 41,005 (74%)
  Yes 1646 (4%) 237 (14%) 1409 (86%) 2.4 (2.1–2.7) 3924 (7%) 710 (18%) 3214 (82%) 1.6 (1.5–1.7)
Cycles ≥3 98,075 24,834 (25%) 73,241 (75%)   141,495 43,012 (30%) 98,483 (70%)  
 FN Events Prior to Cycle of Interest
  No 91,744 (94%) 23,875 (26%) 67,869 (74%) 126,424 (89%) 39,360 (31%) 87,064 (69%)
  Yes 6331 (6%) 959 (15%) 5372 (85%) 2.0 (1.8–2.1) 15,071 (11%) 3652 (24%) 11,419 (76%) 1.4 (1.4–1.5)
Last Cycle 34,860 10,188 (29%) 24,672 (71%)   51,989 20,099 (39%) 31,890 (61%)  
 FN Events Prior to Last Cycle
  No 32,541 (93%) 9774 (30%) 22,767 (70%) 46,115 (89%) 18,215 (39%) 27,900 (61%)
  Yes 2319 (7%) 414 (18%) 1905 (82%) 2.0 (1.8–2.2) 5874 (11%) 1884 (32%) 3990 (68%) 1.4 (1.3–1.5)
All Cycles 190,622 53,065 (28%) 137,557 (72%)   271,944 78,400 (29%) 193,544 (71%)  
 FN Events Prior to Cycle of Interest
  No 182,645 (96%) 51,869 (28%) 130,776 (72%) 252,949 (93%) 74,038 (29%) 178,911 (71%)
  Yes 7977 (4%) 1196 (15%) 6781 (85%) 2.2 (2.1–2.4) 18,995 (7%) 4362 (23%) 14,633 (77%) 1.4 (1.3–1.4)
  1. FN febrile neutropenia
  2. *Only consecutive qualifying cycles, beginning with cycle 1, were considered in this analysis (e.g., in identifying FN events [broad definition] in a prior cycle of the course of interest)